Annie joined Dark Horse in January of 2022, bringing expertise in manufacturing, process optimization, and technology transfer of autologous and allogeneic gene-modified cell therapy products, and passion for workforce development.
Annie joined the CGT field in 2013 at the University of Pennsylvania. While there, she led the team in the manufacture of >100 drug products per year for early-phase clinical trials. With the support of her team, she guided technology transfers and proactively managed the implementation of platform and technology improvements. Annie oversaw development of an accelerated training program that significantly reduced time-to-proficiency for new cell processing technologists and worked to develop and implement a career advancement track to increase retention and foster professional development of cell processing technologists.
During her time at Rocket Pharmaceuticals, Annie provided SME support for external manufacturing and tech transfer activities. She also led laboratory set-up to enable internal process development capabilities and developed training modules to provide cell processing education to facilitate cross-functional engagement.
Before joining the CGT field, Annie devoted 9 years to work as a bench scientist in academia and the non-profit sector, focusing on drug discovery and assay development in liver disease.
Working with Dark Horse has been a natural fit for Annie's skills and knowledge base, and during her time here she has developed an affinity for CMC regulatory projects and the related visibility they offer into real world expectations for different product types at various development stages.
DHC clients have worked with Annie across a range of CMC projects to position their products to successfully meet regulatory expectations. One of Annie's particular strengths is to be able to both identify and mitigate areas that need to be strengthened so as to maximize regulatory and development potential.
Annie lives in the Philadelphia, PA area with her family.